Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT06673602

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Qinhuangdao Hospital of Traditional Chinese Medicine (from the registry)
Registry
  • NCT NCT06673602
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06673602. Randomized; no masking; primary purpose treatment. Start 2024-11-04 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage
Condition
Cognitive Impairment
Condition
Intracerebral Hemorrhage
Intervention (Drug)
FCYC+Conventional treatment
Intervention (Drug)
conventional treatment
Lead sponsor
Qinhuangdao Hospital of Traditional Chinese Medicine (class: other)
Collaborator
Kaifeng Third People's Hospital (class: not stated)
Collaborator
Second Affiliated Hospital of Tsinghua University (class: other)
Collaborator
Weifang Hospital of Traditional Chinese Medicine (class: other)
Collaborator
Shandong Public Health Clinical Center (class: other government)
Collaborator
Kunming Sanbo Brain Hospital (class: not stated)

Record details

Record id
cardio:ct-nct06673602
Content hash
91f9549926e323b2a7bcd7cd3dea3b6eed1a8ba44450c147f789cb602e2737dc